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kindergartens, and schools2. However, studies on the CA-
MRSA prevalence are sporadic. HA-MRSA and CA-MR-
SA can be distinguished by their genetic background, the 
resistance determinant Staphylococcal Cassette Chromo-
some mec (SCCmec), and the presence of Panton-Valentine 
leukocidin (PVL)3. 
The aim of the present study was to investigate the 
molecular epidemiology of MRSA in Primorsko-Goranska 
County of Croatia during a six-year period (2001–2007).
Prevalence of MRSA in Croatia in blood culture iso-
lates was 36,3 %, in 2009 as presented by European Re-
sistance Surveillance System (EARSS) website4.
 Primorsko-Goranska County is situated in western 
part of Croatia, as seen at Figure 1., covering an area of 
3.582 km². Largest city and county center is Rijeka, third 
largest city in Croatia. Public Health and Teaching Insti-
Introduction
Staphylococcus aureus, the most virulent Staphylococ-
cus species, is also second most common isolate from pa-
tients in outpatient settings. S. aureus causes a wide 
range of syndromes, from minor skin and soft tissue infec-
tions to life-threatening pneumonia and toxinosis [1]. 
Rates of methicillin – resistance increased slowly, but pro-
gressively over decades. Increase in methicillin resistance 
worldwide was accompanied by isolation of MRSA isolates 
from community-acquired infections among previously 
healthy individuals with few or not traditional heathcare-
associated risk factors1.
The increase in the rate of CA-MRSA infections is a 
reason for public health concerns, and a challenge for in-
fection control, since MRSA is found in nursing homes, 
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The aim of the study was to investigate the molecular epidemiology of MRSA in Primorsko-Goranska County of 
Croatia during a six-year period (2001–2007). In period from 2001 and 2007, 46 MRSA isolates were collected in Rijeka, 
strains were subjected to susceptibility testing according to CLSI guidelines, mecA gene detection and SCCmec typing as 
well as detection of PVL. Strains were typed by Pulse Field Gel Electrophoresis (PFGE) and spa typing. All isolates were 
susceptible to vancomycin, linezolid, mupirocin, nitrofurantoin, only one strain was resistant to fusidic acid and co-tri-
moxazole. Results of SCCmec typing showed the presence of SCCmec type IV in 26 MRSA strains, SCCmec type V in three 
strains, and 13 strains comprised SCCmec I. SCCmec type II and III were not observed. Four MRSA strains were non-
typeable by applied SCCmec typing methods. PVL was detected in 4 strains, two SCCmec IV and two SCCmec V. PFGE 
analysis, grouped MRSA strains into six similarity groups and 18 singletons. Dominating spa types in this collection of 
strains were t015, with 15 strains, followed by t041 (N=7), t051, (N=2 ), t2850 (N=2), t008 (N=2) and single isolates t441, 
t002, t448, t018, t019, t355, t390, t026, t449, t148. We also detected two new spa types, t3510 and t3509, respectively. This 
is the fi rst report on SCCmec type V in Croatia, and, to our knowledge, fi rst report of PVL-positive mehicillin-resistant 
Staphylococcus aureus SCCmec type V and t441 (ST59-MRSA-V) in this part of Europe.
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tute in Rijeka is leading public health and teching institu-
tion in county with gravitating population of approximate-
ly 300 000 inhabitants (around 7% of Croatian population.). 
Department of microbiology mainly process specimens 
from outpatient population and ambulatory care. 
Methods
In period from 2001 and 2007, all MRSA strains iso-
lated (N=46) were collected and stored until further anal-
ysis. Strains originated from nasal swabs (N=20), 15 from 
wound swabs, and two or one isolate per following sites: 
skin infection sample, furuncullus, conjunctiva, tongue.
All isolates were identifi ed based on colony morphology, 
catalase, coagulase and DNA-se presence. Isolates were 
screened for MRSA with oxacillin, cefoxitin disk and latex 
agglutination test.
All 46 MRSA strains were subjected to further analy-
sis in Clinical Hospital Centre Zagreb, Department of 
Clinical and Molecular Microbiology and some non-type-
able strains were submitted to University Hospital Maas-
tricht, Mastricht Infection Center for additional typing.
Susceptibility testing was performed according to 
CLSI guidelines5 for the following antibiotics: penicillin, 
oxacillin, cefoxitin, erythromycin, clindamycin, azythro-
mycin, gentamycin, tetracycline, rifampicin, trimetho-
prim/sulfamethoxazole, linezolid, ciprofl oxacin, vancomy-
cin, nitrofurantoin, trimethoprim, except for fusidic acid 
and mupirocin, which were interpreted according to the 
criteria of the French Society of Microbioogy (CAFM)6.
mecA gene detection and SCCmec typing was per-
formed according to Oliveira et al.7 with some modifi ca-
tions according to Deurenberg et al.8 and for some strains, 
fl uorescent PCR assay was used9, partially based on 
Zhang multiplex PCR method10. Detection of PVL was 
performed as previously described11.
Pulse Field Gel Electrophoresis (PFGE) was performed 
as previously described12.
PFGE patterns were analyzed and compared with use 
of GelCompar III software (Applied Maths, Sint-Martens-
Latem, Belgium). Spa typing was performed according to 
SeqNet protocol, spa types were assigned by using Ridom 
Spa software (Ridom, GmbH, Germany) and synchroniza-
tion with Ridom server13.
BURP alligment was used for spa CC alligment.
Results
All strains were resistant to penicillin, oxacillin and 
cefoxitin, 35% were resistant to erythromycin, 30% to clin-
damycin, 35% to azythromycin, 30% to gentamycin, 2% to 
tetracycline (17,4 % were intermediate resistant to tetra-
cycline), 13% to rifampicin (4% intermediate resistant to 
rifampicin), 37 % to ciprofl oxacin (2% intermediate resist-
ant to ciprofl oxacin), 4,3% to trimethoprim (2% intermedi-
ate resistant to trimethoprim). All isolates were suscepti-
ble to vancomycin, linezolid, mupirocin, nitrofurantoin, 
only one strain was resistant to fusidic acid and co-trimox-
azole.
Typing results are shown in Figure 1.
All isolates were mecA positive. Results of SCCmec typ-
ing showed the presence of SCCmec type IV in 26 MRSA 
strains, SCCmec type V in three strains, and 13 strains 
comprised SCCmec I. SCCmec type II and III were not ob-
served in study collection.
Four MRSA strains were non-typeable by applied SC-
Cmec typing methods.
PVL was detected in 4 strains, two SCCmec IV and 
two SCCmec V.
PFGE analysis, using Tenover criteria, grouped MRSA 
strains into six similarity groups (A, B, C, D, E, F) con-
taining 9, 9, 6, 2, and 2 isolates, respectively, and 18 sin-
gletons.
Dominating spa types in this collection of strains were 
t015, with 15 strains, followed by t041 (N=7), t051, (N=2 ), 
t2850 (N=2), t008 (N=2) and single isolates t441, t002, 
t448, t018, t019, t355, t390, t026, t449, t148. We also de-
tected two new spa types, t3510 and t3509, respectively.
MRSA strains SCCmec type V are spa typed as t002 
(assigned ST-5), t355 (assigned ST-377) , t441 (assigned 
ST-59). 
Isolates were classifi ed into 2 clusters: CC 1 with t008, 
t024 and t051, and other cluster, CC41 consisting of t002, 
t041 and t2027.
Discussion
With efforts to prevent the spread of MRSA in hospi-
tals and raised awareness of possible routes of transmis-
sion, encouraged by hospital administration and, in some 
counties, media campaign and Government involvement, 
the MRSA rates decreased in some countries14. 
Worrying are reports and suggestions that CA MRSA 
is more and more present in hospitals. Children, young 
without risk factors are carriers and sometimes, hey de-
velop clinical infection, ranging from mild skin infection 
to severe skin and soft-tissue infections, pneumonia15,16 
etc. CA- MRSA strains can cause infections with rapidly 
progressive, fatal diseased including necrotizing pneumo-
nia, severe sepsis and necrotizing fasciitis1. 
There are few data on prevalence and structure of 
community-associated MRSA strains in Europe17–19 al-
though some report are showing increase in this distinct 
population of bacteria. In USA, majority of bloodstream 
infections20 and especially skin and soft tissue infections21 
are caused by CA MRSA.
Genetic backgrounds of CA-MRSA isolates are distinct 
in different geographic locations22,11 and many different 
backgrounds can exist within a narrow geographic area. 
The most widely used molecular typing method for 
study of MRSA epidemiology is Pulse Field Gel Electro-
phoresis, PFGE, suitable method for the determination of 
clonal relationships but not for long term epidemiological 
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investigation. Spa typing is proposed as and accurate 
method for typing of S. aureus23, and it has the advan-
tages of speed, interpertation and interlaboratory com-
parison.
In this study, we combined sequnce-based, single locus-
oriented spa typing method with whole-genome, restric-
tion-based methods in order to compare isolates within 
larger time frame. For complete nomenclature of MRSA it 
is important to perform SCCmec typing as well.
Our previous reports suggested the dominance of ST-
247/250 MRSA-I among MRSA strains described24 and in 
collection of strains in 2004 (data not shown). 
There were sporadic reports on community-associated 
MRSA in Croatia25, isolated from non-infected body sites 
or skin and soft tissue infections, but this is the fi rst report 
on SCCmec type V in Croatia, and, to our knowledge, in 
this part of Europe. 
In this study we showed presence of PVL-positive 
strains, in four cases. Some epidemiologic and clinical 
Fig. 1. Dendrogram of MRSA strains from Rijeka.
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data provide compelling evidence that the high virulence 
potential of CA-MRSA is associated with genes lukS-PV 
and lukF-PV( pvl) encoding the subunits of the Panton-
Valentine leukocidin.
Seems that clinical sequelae of pvl- positive infections 
are more severe than pvl-negative S. aureus26. 
The interesting fi nding is that half of PVL-positive 
isolates is characterized as MRSA SCCmec V, which is not 
an common fi nding, described in severe infection in 
Greece27, but within different clonal lineage (ST-80).
SCCmec type V is typical for Australia but is usually 
PVL-negative. Strains causing infections with SCCmec V 
and PVL positive; ST 59 are observed in Taiwan, espe-
cially in children. This clone, observed in Taiwan is also 
present in hospitals in signifi cant proportion[28].
This work is showing that there is a certain number of 
MRSA strains in the community of this area, with heter-
ogenous background. This is in concordance with similar 
studies in some European countries29.17,18, but some clonal 
lineages are desribed in this region (Southern Eastern 
Europe) for the fi rst time. 
Predominant spa type in this collection of strains, t015 
is observed in Croatia, in eastern, western parts of coun-
try, and Istria, area which is situated close to Primorsko-
goranska county. 
It is obvious that some strains, although not having 
typical and direct hospital background, ended originated 
in hospitals, which is well known for spa type t041.
t041 is an frequently encountered spa type in Croatia, 
and characterizing typical hospital-associated MRSA to-
gether with SCCmec type I, also found in Italy [30].Two 
of predominating spa types are grouped in two major 
similarity groups, B, C and D, based on PFGE typing. 
There are some overlaps, and singletons are not grouped 
in between genetically related strains.
t002 is common spa type, isolated in Germany, Aus-
tria, Spain, Israel, Canada, USA, UK,
Switzerland etc31–33,13,30.
spa type t355 is observed in Austria, Slovenia, Ger-
many, Norway, Netherlands, Turkey, Israel, Sweden, Ice-
land, Finland, France13,34.
Strains typed as t441 were previously observed in Swe-
den, Norway, Netherlands, Iceland, Taiwan13.
In conclusion, CA-MRSA isolates have been emerging 
around the world in different S. aureus genetic lineages 
and are beginning to enter in healthcare environments 
where they could become endemic.
The strong epidemiologic link between PVL and CA-
MRSA disease leaves little doubt that PVL must play an 
important role in the pathogenesis and course of disease; 
however, Croatian SCCmec IV MRSA isolates were most-
ly PVL-negative, and there were SCCmec V-PVL postive 
isolates which suggests that there is a lot of genetic ex-
change and variability among MRSA isolates from com-
munity.
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PRVI IZOLAT STAPHYLOCOCCUS AUREUS REZISTENTNOG NA METICILIN SCCMEC TIPA V, 
POZITIVAN NA PVL
S A Ž E T A K
Cilj studije je bio istražiti epidemiološke i molekulne karakteristika MRSA izolata iz Primorsko-Goranske županije 
tijekom šestogodišnjeg perioda. U periodu od 2001. Do 2007. godine, 46 MRSA izolata je prikupljeno, testirana je osjetlji-
vost na antimikrobne lijekove prema CLSI smjernicama, također je provedena detekcija mecA gena, SCCmec tipizacija 
i detekcija PVL kodirajućih gena. Tipizacija sojeva dodatno je upotpunjena analizom elektroforeze u pulsirajućem polju 
(PFGE analizom) i tipizacijom spa lokusa. Svi MRSA izolati su osjetljivi na vankomicin, linezolid, mupirocin, nitrofu-
rantoin, samo jedan soj je bio rezistentan na fucidinsku kiselinu i ko-trimoksazol. Rezultati SCCmec tipizacije pokazali 
su prisutnost SCCmec tipa IV u 26 MRSA sojeva, SCCmec tipa V kod tri izolata, a 13 sojeva je imalo SCCmec I. SCCmec 
tipovi II i III nisu nađeni. Četiri MRSA su bila netipabilna navedenom metodom. PVL je detektiran kod 4 soja, dva SC-
Cmec IV I dva SCCmec V. PFGE analiza grupirala je MRSA sojeve u 6 grupa sličnosti  18 pojedinačnih, nesvrstanih 
sojeva. Dominantni spa tipovi u ovoj kolekciji sojeva su bili: t015, s 15 sojeva, te t041 (N=7), t051, (N=2 ), t2850 (N=2), 
t008 (N=2) i s po jednim izolatom tipiziranim kao: t441, t002, t448, t018, t019, t355, t390, t026, t449, t148. Otkrili smo 
i nove tipove, t3510 i t3509. Ovo je prvi spomen o prisutnosti SCCmec tipa V u Hrvatskoj, i, prema našem saznanju, prvo 
izvješće od PVL-pozitivnom MRSA s SCCmec tipom V i spa tipom t441 (ST59-MRSA-V) u ovom dijelu Europe.
